Related Experiment Video
Updated: Jul 21, 2026
A Swine Model of Neonatal Asphyxia
Published on: October 11, 2011
Caffeine citrate for apnea of prematurity-One dose does not fit all a prospective study
Chava Rosen1,2,3, Camilia Taran4, Marwan Hanna4
1Department of Neonatology, Edmond and Lily Safra Children's Hospital, Sheba Medical Center, Tel-Hashomer, Israel. chava.rosen@weizmann.ac.il.
Insights
Standard-dose caffeine citrate effectively treats apnea of prematurity in neonates. Higher initial doses may be more beneficial for infants born at or before 29 weeks gestation.
Area of Science:
- Neonatology
- Pharmacology
- Pediatrics
Background:
- Caffeine citrate is the standard treatment for apnea of prematurity in preterm neonates.
- Optimal dosing strategies for caffeine citrate remain undefined, leading to varied clinical practices.
- This study investigates the clinical efficacy of standard-dose caffeine citrate in a preterm neonate population.
Purpose of the Study:
- To evaluate the clinical response of preterm neonates to standard-dose caffeine citrate.
- To identify factors influencing treatment response and outcomes.
- To assess the safety and potential benefits of higher initial caffeine citrate doses.
Main Methods:
- A prospective observational study was conducted in a Neonatal Intensive Care Unit (NICU).
- The study included 66 preterm neonates with a gestational age less than 33 weeks.
- Infants received caffeine citrate treatment according to the local NICU protocol.
Main Results:
- Thirty infants responded to the standard 7.5 mg/kg dose, while 36 required an increase to 10 mg/kg.
- Non-responders were born at an earlier gestational age (29 vs. 31 weeks) and had longer hospital stays.
- Non-responders also required significantly longer supplemental oxygen support compared to responders.
Conclusions:
- Initiating caffeine citrate at higher doses is safe and may not necessitate routine serum level monitoring.
- Higher initial doses of caffeine citrate could be more effective in managing apnea of prematurity, particularly in infants born at or before 29 weeks gestation.
Background:
Caffeine citrate is the most frequently used medication in preterm neonates for the prevention of apnea of prematurity. There is no accepted consensus regarding the optimal caffeine citrate dosing. In this study, we evaluate clinical responses of premature neonates to standard-dose caffeine citrate treatment.
Methods:
A prospective observational study conducted at the NICU at Sheba Medical Center (3/2016-2/2017). The study population included preterm neonates born at a gestational age (GA) < 33 weeks and treated with caffeine citrate according to the local NICU protocol.
Results:
The study cohort included 66 preterm neonates of GA < 33 weeks. Thirty infants were defined as responders and 36 as nonresponders to 7.5 mg/kg caffeine citrate treatment, and they required a further dose increase to 10 mg/kg. Infants in the nonresponders group were born at earlier GA than responders (29 vs. 31 weeks, respectively, P = 0.004). The nonresponders required a significantly longer hospital stay (56 vs. 46 days, P = 0.014), and longer supplemental oxygen support (18 vs 2 days, P = 0.008).
Conclusions:
Caffeine citrate initiation at higher doses is safe and does not require routine serum levels monitoring. It might be more effective for controlling apnea of prematurity in preterm neonates born ≤29 weeks of gestation.
